Top Markets
#1 Smilek to the Bank Smilek to the Bank +50.56%
#2 Purr Purr +39.21%
#3 OriginTrail OriginTrail +21.06%
#4 ApeX ApeX +18.59%
#5 Zora Zora +17.74%
#6 Morpho Morpho +17.47%
#7 龙虾 (Lobster) 龙虾 (Lobster) +16.50%
#8 Non-Playable Coin Non-Playable Coin +16.01%
#9 Wrapped XPL Wrapped XPL +15.54%
#10 UnifAI Network UnifAI Network +15.45%
Coin of the day
Smilek to the Bank Smilek to the Bank
Settings
Language
ENGLISH
Currency
USD
Theme
Polaryx Therapeutics, Inc. Common Stock Polaryx Therapeutics, Inc. Common Stock

Polaryx Therapeutics, Inc. Common Stock

PLYX
Rank in Stocks #21586
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to... Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
Share Price
$2.10
Last synced: 2026-08-21
Market Cap
$104.43M
Change (1 day)
-2.10%
Change (1 year)
-
Country
US
Trade Polaryx Therapeutics, Inc. Common Stock (PLYX)

Category

Healthcare
Revenue for Polaryx Therapeutics, Inc. Common Stock (PLYX)
Revenue in Aug 2026 TTM: 0
According to Polaryx Therapeutics, Inc. Common Stock latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Polaryx Therapeutics, Inc. Common Stock from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH